Skip to content
Specimen Atlas of Research Peptides30 plates · MIT
PeptidesDBan atlas
Side-by-side · Research reference

AOD-9604vsTB-500

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

APhase 2Reviewed10/47 cited
BPhase 2Reviewed8/46 cited
AOD-9604
HGH 176-191 · β3-AR Lipolytic
250–300 mcgDaily doseHeffernan 2001
Phase 2Evidence levelHeffernan 2001Ng 2008
~30 minHalf-life
SQ · Abdomen · Daily fasted
TB-500
Thymosin β4 fragment · Healing
2 mgPer doseGoldstein 2012
Phase 2Evidence levelGoldstein 2012
~2 hrHalf-life
SQ or IM · Multiple sites · 2–3×/week

01Mechanism of Action

Parameter
AOD-9604
TB-500
Primary target
β3-adrenergic receptor (proposed)Ng 2008
G-actin (sequestering) + cell-surface integrinsGoldstein 2012
Pathway
β3-AR activation → cAMP → hormone-sensitive lipase activation → triglyceride breakdown to FFA + glycerolNg 2008
Actin remodelling → cell migration; integrin-linked signaling → angiogenesis; anti-inflammatory cytokine modulationGoldstein 2012Malinda 1999
Downstream effect
Lipolysis of adipose tissue triglycerides; FFA release for oxidation; minimal IGF-1 / insulin impactHeffernan 2001
Accelerated wound healing, endothelial migration, hair follicle regeneration, cardiac repair (preclinical)Goldstein 2012
Feedback intact?
No GH-axis or IGF-1 feedback
Endogenous protein at baseline; supplementation amplifies
Origin
Synthetic modified C-terminal hexadecapeptide fragment of human GH (176-191) with N-terminal Tyr substitutionNg 2008
17-AA active fragment of endogenous 43-AA thymosin β4 (TMSB4X gene)Goldstein 2012
Antibody development
—
—

02Dosage Protocols

Parameter
AOD-9604
TB-500
Standard dose
250–300 mcg / dayHeffernan 2001
Anecdotal SQ range. Phase 2 trial dose 1 mg/day oral.
2 mg per injectionGoldstein 2012
Anecdotal community range; clinical Phase 2 trials used 70–840 mcg/kg IV.
Frequency
Once daily, fasted
2× per week (loading); then 1× per week (maintenance)
Lower / starter dose
150 mcg / day
1 mg per injection
Evidence basis
Phase 2 trials + animal-strongHeffernan 2001Ng 2008
Animal-strong + Phase 2 dermal/ocular trialsGoldstein 2012
Duration
8–12 weeks per cycle
4–8 weeks loading; longer maintenance for chronic injury
Reconstitution
Bacteriostatic water, 1 mL per 2 mg vial → 2 mg/mL
Bacteriostatic water, 1–2 mL per 5 mg vial
Timing
Morning fasted preferred (pre-cardio)
Aligns with circadian lipolysis.
Evening or pre-rest preferred (anecdotal)
Half-life
~30 min plasma
~2 hours (estimated; tissue uptake longer)

04Side Effects & Safety

Parameter
AOD-9604
TB-500
Injection site reaction
Mild erythema
Mild erythema, transient pain
GI symptoms
Rare mild nausea
Rare nausea (anecdotal)
Cardiovascular
Possible mild HR increase via β3-AR (theoretical β1 cross-reactivity)
—
IGF-1 elevation
None — designed to lack GH-axis activityHeffernan 2001
—
Insulin sensitivity
Neutral — no glucose impairmentHeffernan 2001
—
Cancer risk
No GH/IGF-1 axis activity → lower theoretical risk vs HGH
Theoretical via angiogenesis pathway
Pregnancy / OB
Avoid
Avoid
Lethargy / fatigue
—
Reported anecdotally during loading phase
Antibody formation
—
No data (no long-term human trials)
Long-term safety
—
Unknown beyond Phase 2
Absolute Contraindications
AOD-9604
  • ·Pregnancy / breastfeeding
  • ·Severe cardiovascular disease (caution with β-receptor agonists)
TB-500
  • ·Active malignancy (theoretical angiogenesis concern)
  • ·Pregnancy / breastfeeding
Relative Contraindications
AOD-9604
  • ·Concurrent β-blocker therapy (theoretical antagonism)
  • ·Pheochromocytoma
TB-500
  • ·Cancer history
  • ·Concurrent VEGF inhibitor therapy

05Administration Protocol

Parameter
AOD-9604
TB-500
1. Reconstitution
Add 1 mL bacteriostatic water to 2 mg vial → 2 mg/mL = 200 mcg per 0.1 mL.
Add 1–2 mL bacteriostatic water to 5 mg vial → 2.5–5 mg/mL. Roll gently.
2. Injection site
SQ — abdomen preferred. Rotate sites.
SQ near injury site (preferred), or systemic SQ (abdomen). Rotate sites.
3. Timing
Morning, fasted, ideally pre-cardio for amplified fat oxidation.
Evening or pre-sleep is most common anecdotal timing.
4. Storage
Lyophilised: room temp, light-protected. Reconstituted: refrigerate, ≤30 days.
Lyophilised: room temp, light-protected. Reconstituted: refrigerate, ≤30 days.
5. Needle
29–31G, 4–8 mm insulin syringe.
27–31G, 4–8 mm insulin syringe.

06Stack Synergy

AOD-9604
+ MOTS-c
Moderate
View MOTS-c →

AOD-9604 mobilises FFAs from adipose via β3-AR; MOTS-c upregulates AMPK / PGC-1α / FAO machinery so that mobilised FFAs are efficiently oxidised. The pathways are sequential — supply (AOD) plus demand (MOTS-c) — and produce more durable lipolytic effects than either alone in anecdotal protocols.

AOD-9604
250–300 mcg SQ · morning fasted (daily)
MOTS-c
5 mg SQ · 2–3× per week (pre-workout)
Primary benefit
Fat mobilisation + mitochondrial oxidation, no IGF-1 concern
TB-500
+ BPC-157
Strong
View BPC-157 →

TB-500 and BPC-157 cover complementary halves of tissue repair: BPC-157 upregulates VEGFR2-driven angiogenesis and fibroblast outgrowth; TB-500 sequesters G-actin to enable endothelial / epithelial migration. The anecdotal canonical "healing stack" — pairs especially well for tendon and ligament injuries.

TB-500
2 mg SQ · 2× per week
BPC-157
250–500 mcg SQ · daily
Primary benefit
Combined angiogenesis + cell migration for tendon/ligament/muscle repair